2020 ESC Guidelines on Adult Congenital Heart Disease

The 2020 European Society for Cardiology guidelines for the management of adult congenital heart disease provide new concepts and important revisions to the previous guidelines, issued a decade ago.

EXPLORER-HCM: Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by unexplained left ventricular (LV) hypertrophy associated with dynamic LV outflow tract obstruction. Current medical therapies are nonspecific and have limited efficacy in relieving symptoms. Mavacamten is a first-in-class targeted inhibitor of cardiac myosin, which has been shown to reduce LV outflow tract obstruction, improve exercise capacity, and relieve symptoms of oHCM in the PIONEER-HCM phase 2 study.

IMPACT-Afib Implementation of Stroke Prevention in Atrial Fibrillation

IMPACT-AFib is an initiative to explore the effect of educating patients with atrial fibrillation (AFib) and their providers about the importance of anticoagulation medications for reducing the risk of stroke. The goal of this initiative is to find out whether the materials you received in the mail and on this website improve the use of oral anticoagulant medications for stroke prevention in patients with atrial fibrillation.

Tackling cardiovascular diseases with a new generation of polypills

Dyslipidemia and hypertension are the most important risks factors of cardiovascular diseases The more frequent use of a new generation of polypills is the best way to optimize adherence to treatment and thus prognosis in cardiovascular patients.

ESC Gold Medal 2020 Winner: Kari Stefansson

Doctor Kári Stefánsson is CEO of deCODE genetics (Reykjavík, Iceland), a company that he founded to analyse and understand the human genome. With Dr. Stefánsson at the helm, deCODE has discovered key genetic risk factors for several common conditions, including cardiovascular diseases. For his far-reaching contribution to science, the ESC has awarded Dr. Stefánsson the ESC Gold Medal and he will today give the ESC Awards Inspirational Lecture entitled: ‘Population data on human diversity; a key to the understanding of common disease of man.’

ESC Gold Medal 2020 Winner: Stefanie Dimmeler

In recognition of her outstanding achievements, Stefanie Dimmeler is honored with the gold medal of the European Society for Cardiology. She receives the award for her research work that has contributed to a better understanding of cardiovascular diseases and to the development of new treatment approaches.

PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients

Showcase PCSK9i mAbs from pre-clinical development to real-world data Consider the vast amount of evolocumab data across multiple indications in real-world settings Differentiate PCSK9i mAb from other therapeutic opportunities.

BRACE CORONA: Continuing vs. Suspending ACE Inhibitors and ARBs in COVID-19

The results of the BRACE CORONA trial revealing that temporarily suspending use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) did not show clinical benefit in patients hospitalized with mild to severe COVID-19.

2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease

Prof. Sanjay Sharma helping us to review the key messages and the importance of the new 2020 ESC guidelines on sport cardiology.

LoDoCo2 Low-Dose Colchicine in Coronary Disease

A significantly lower occurrence of cardiovascular events was observed in chronic coronary disease patients receiving low-dose colchicine compared with those receiving placebo, according to results from the LoDoCo2 trial published in the New England Journal of Medicine and presented at ESC Congress 2020.

HOME-PE - Hospitalisation or Outpatient Management of PE Patients - HESTIA vs. Simplified PESI

The goal of the trial was to evaluate two risk stratification tools among patients diagnosed with pulmonary embolism (PE).

ESC 2020: Best clinical cases - Awards session

The best clinical case Award Session is composed of the best cases selected for a presentation during ESC Congress.

Persistence and cardiovascular outcomes with ramipril, atorvastatin, ASA as a single pill compared to the multi pill combination. A subanalysis of the START study, a claims data analysis

Large randomized clinical trials have shown the efficacy of aspirin (ASA), angiotensin converting enzyme inhibitors (ACEI) and statins (S) in secondary prevention. However, adherence to medication is low in patients suffering from a cardiovascular event and decreases with each additional tablet. Therefore, a single pill (SP) approach is considered to increase drug persistence and decrease cardiovascular events in this patient population.

PARALLAX: Sacubitril/Valsartan versus Individualized RAAS Blockade in Patients with HFpEF

While sacubitril/valsartan reduced N-terminal pro B-type natriuretic peptide (NT-proBNP), it did not improve functional capacity compared to individualized background therapy in patients with heart failure with preserved ejection fraction (HFpEF), according to findings from the PARALLAX trial presented at ESC Congress 2020.

Time to reduce the implementation gaps-the role of PCSK9i in routine practice

Professor Kausik K. Ray helping us to understand the role of LDL-C lowering in Guidelines.

BPLTTC - Blood Pressure Lowering for Prevention of Cardiovascular Events across Different Levels of Blood Pressure

Blood pressure-lowering medication can prevent heart attacks and strokes – even in people with normal blood pressure, based on new research from the BPLTTC trial presented at ESC Congress 2020.